Cost‐Effectiveness of New Direct‐Acting Antivirals to Prevent Post–Liver Transplant Recurrent Hepatitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-6143|15|7|1817-1826

ISSN： 1600-6135

Source： AMERICAN JOURNAL OF TRANSPLANTATION, Vol.15, Iss.7, 2015-07, pp. : 1817-1826

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct‐acting anti‐virals

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 866-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 791-793

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

By  

Oncology, Vol. 91, Iss. 6, 2016-10 ,pp. : 341-347

Karger

Access to resources Recommend Favorite

Treatment of hepatitis C: the use of the new pangenotypic direct‐acting antivirals in “special populations”

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 28-33

John Wiley & Sons Inc

Access to resources Recommend Favorite

P151: Improvement of virologic response and liver elasticity in HCV‐patients after liver transplantation through treatment with the new direct‐acting antivirals

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 94-95

John Wiley & Sons Inc

Access to resources Recommend Favorite